Results from Astrazenca's Pegasus study of its blood-thinning Brilinta treatment received a cool reaction from the market on Monday, though analysts at UBS maintained their positive outlook for the product.The bank, which kept a 'buy' rating and 5,500p target price for the stock, said it still sees upside to consensus forecasts for Brilinta's sales despite the mixed study results.In spite of a number of headwinds facing Vodafone, JPMorgan Cazenove has retained an 'overweight' stance on the stock, saying it still expects a return to revenue growth at the telecoms group in the second half of 2015."Whilst these overhangs may persist short term, April should see attention refocus onto the full-year results and Vodafone's improving European outlook. Crucially we anticipate ongoing sequential improvements in organic revenue growth, with this largely predicated on Southern Europe, and believe this should enable Vodafone to return to growth in H2, supporting a material multiple re-rating," said JPMorgan analyst Akhil Dattani.Recent housing data has added to concerns in the housebuilding sector of a slowdown in the London housing market, according to Westhouse Securities, which warned of a potential "overhang" of new properties going up in the capital."A key concern, in our view, going forward is the sheer weight of new build properties currently under construction or going through the planning system in London," said analyst Alastair Stewart. "Other statistics we have seen indicate the total number of homes under construction in London is considerably higher than at the last peak in 2007 and this could present a mounting 'overhang' during the next 12 - 36 months, particularly in a cluster of 'hotspots' near the densest development zones."
Last checked at 
